Laser Focus World is an industry bedrock—first published in 1965 and still going strong. We publish original articles about cutting-edge advances in lasers, optics, photonics, sensors, and quantum technologies, as well as test and measurement, and the shift currently underway to usher in the photonic integrated circuits, optical interconnects, and copackaged electronics and photonics to deliver the speed and efficiency essential for data centers of the future.

Our 80,000 qualified print subscribers—and 130,000 12-month engaged online audience—trust us to dive in and provide original journalism you won’t find elsewhere covering key emerging areas such as laser-driven inertial confinement fusion, lasers in space, integrated photonics, chipscale lasers, LiDAR, metasurfaces, high-energy laser weaponry, photonic crystals, and quantum computing/sensors/communications. We cover the innovations driving these markets.

Laser Focus World is part of Endeavor Business Media, a division of EndeavorB2B.

Laser Focus World Membership

Never miss any articles, videos, podcasts, or webinars by signing up for membership access to Laser Focus World online. You can manage your preferences all in one place—and provide our editorial team with your valued feedback.

Magazine Subscription

Can you subscribe to receive our print issue for free? Yes, you sure can!

Newsletter Subscription

Laser Focus World newsletter subscription is free to qualified professionals:

The Daily Beam

Showcases the newest content from Laser Focus World, including photonics- and optics-based applications, components, research, and trends. (Daily)

Product Watch

The latest in products within the photonics industry. (9x per year)

Bio & Life Sciences Product Watch

The latest in products within the biophotonics industry. (4x per year)

Laser Processing Product Watch

The latest in products within the laser processing industry. (3x per year)

Get Published!

If you’d like to write an article for us, reach out with a short pitch to Sally Cole Johnson: [email protected]. We love to hear from you.

Photonics Hot List

Laser Focus World produces a video newscast that gives a peek into what’s happening in the world of photonics.

Following the Photons: A Photonics Podcast

Following the Photons: A Photonics Podcast dives deep into the fascinating world of photonics. Our weekly episodes feature interviews and discussions with industry and research experts, providing valuable perspectives on the issues, technologies, and trends shaping the photonics community.

Editorial Advisory Board

  • Professor Andrea M. Armani, University of Southern California
  • Ruti Ben-Shlomi, Ph.D., LightSolver
  • James Butler, Ph.D., Hamamatsu
  • Natalie Fardian-Melamed, Ph.D., Columbia University
  • Justin Sigley, Ph.D., AmeriCOM
  • Professor Birgit Stiller, Max Planck Institute for the Science of Light, and Leibniz University of Hannover
  • Professor Stephen Sweeney, University of Glasgow
  • Mohan Wang, Ph.D., University of Oxford
  • Professor Xuchen Wang, Harbin Engineering University
  • Professor Stefan Witte, Delft University of Technology

Verona Pharma (NASDAQ: VRNA) Reports its Phase 3 ENHANCE-2 Trial of Ensifentrine Met Primary Endpoint in Treating COPD

Verona Pharma plc (NASDAQ: VRNA) is engaged as a clinical-stage biopharmaceutical company, which is focused on the research, development and commercialization of next-generation treatments for respiratory diseases. Shares of the biopharma company are soaring 59% through early trading on Tuesday, August 9, 2022. Over the past three months, Verona Pharma has seen average daily volume of 91,990 shares. However, volume of 27.72 million shares or dollar volume of around $336.8 million, has already exchanged hands through early trading.

Shares of Verona Pharma are surging after the company released top-line results from its Phase 3 ENHANCE-2 clinical trial of ensifentrine for the treatment of chronic obstructive pulmonary disease (COPD). Not only were the primary endpoints successfully met, management noted that its secondary endpoints were also achieved during the trial. Ensifentrine is a first-in-class, dual inhibitor of enzymes phosphodiesterase 3 and 4 combining bronchodilator and anti-inflammation capabilities into one treatment.

The primary endpoint was met after the treatment group saw statistically significant improvements in COPD severity, inhaled corticosteroids (ICS) use, chronic bronchitis, and more. Ensifentrine demonstrated a 42% reduction in moderate-to-severe COPD exacerbations over a 24 week period compared to the placebo group. Quality of life measurements showed improvements in the treatment group, which demonstrates the drug candidate’s ability to improve lung function and reduce COPD episodes.

The drug candidate demonstrated a strong safety profile, which showed the treatment was well tolerated among the test group and in-line with results from the placebo group. Management says they plan to submit its Phase 3 trial full report before the end of 2022. In addition, Verona Pharma says they will submit a New Drug Application with the U.S. Food and Drug Administration during the first half of 2023.

Antonio Anzueto, MD, Professor of Medicine and Section, Chief of Pulmonary at South Texas Veterans Healthcare System, commented: “Ensifentrine has demonstrated clear improvements in lung function in addition to favorable safety results. I am extremely excited by the clinically meaningful 42% reduction in the rate of exacerbations observed over 24 weeks in these symptomatic patients, many receiving background therapy. Based on these meaningful results, I believe ensifentrine, if approved, will be an important new class of bronchodilator and non-steroidal anti-inflammatory therapy for COPD patients providing a much needed alternative to existing treatments.”

Disclosure: No position. Spotlight Growth has no relationships with any of the companies mentioned in this article and did not receive payment in any form for its creation. This is an opinion article and is not meant to be financial advise. We are not broker-dealers or investment professionals. Please conduct your own due diligence. For more information on our disclosures, please visit: https://spotlightgrowth.com/disclosures/

The post Verona Pharma (NASDAQ: VRNA) Reports its Phase 3 ENHANCE-2 Trial of Ensifentrine Met Primary Endpoint in Treating COPD appeared first on Spotlight Growth.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.